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COST-EFFECTIVENESS OF SPONGE-BASED SURVEILLANCE WITH GENETIC TESTING  
FOR EARLY DIAGNOSIS OF ESOPHAGEAL ADENOCARCINOMA
Introduction
Esophageal adenocarcinoma (EAC) is a deadly cancer with 
increasing incidence rates over the past three decades [1] and 
a 5-year relative survival of individuals diagnosed with EAC of 
only 14% [2]. Barrett’s Esophagus (BE) is a major risk factor 
for developing EAC. BE is often preceded by a diagnosis of 
gastroesophageal reflux disease (GERD) [3]. Epidemiological 
studies have identified important individual-level risk factors for 
development of BE, including gender, race/ethnicity, age, duration 
of GERD symptoms, smoking, and obesity [4-5]. Numerous cost-
effectiveness analyses have established that endoscopic screening 
and surveillance in high-risk patients for BE and BE with dysplasia 
is not cost-effective [6-7]. Non-endoscopic methods have been 
proposed [8] yet few studies have evaluated their cost-effectiveness 
against endoscopic methods [9]. Complementing non-endoscopic 
sponge-based methods with a genetic test for early detection of 
BE with dysplasia may lead to early diagnosis and reduce risk of 
developing EAC. 
Aims
To compare health benefits and costs-effectiveness of current 
(endoscopy+biopsy) and alternative (sponge-based cytological 
sampling with genetic testing) surveillance strategies for early 
detection of Barrett’s esophagus, which is a risk factor for 
esophageal adenocarcinoma.
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Methods
A microsimulation model was developed to track individual-level 
health trajectories accounting for: 
i. demographic and lifestyle risk factors for developing Barrett’s 
esophagus (BE); 
ii. medication use, screening/ surveillance for BE; 
iii. treatment algorithms for each health state using established 
guidelines and expert opinion (Figure 1).
Two surveillance strategies were tested: 
i. endoscopy+biopsy (baseline);
ii. sponge-based cytological sampling followed by genetic test 
precursors to EAC (alternative).
Clinical outcomes were compared under each surveillance strategy 
and cost-utility analysis was used to estimate average lifetime costs 
(2014 Canadian dollars) and health benefits (quality-adjusted life 
years, QALYs) per person. Sensitivity analysis (deterministic and 
probabilistic) and value-of-information analysis were also performed.
Results
Calibrated model matched well with the observed data and had low 
absolute percent error values with a 7% and 13% error for the male 
and overall EAC incidence rate, respectively. Model validation results 
also showed good comparisons with observed data on EAC incidence 
rates (Figure 2). Under the alterative surveillance strategy, EAC 
incidence rates were reduced by up to 40% under increased sensitivity 
of the genetic test for dysplasia in NDBE patients. 
Cost-effectiveness of the alternative strategy was dependent on the 
percent uptake of the alternative strategy and percent increase in 
sensitivity of the genetic test. Under 100% uptake of sponge-based 
genetic testing and 50% improvement in sensitivity relative to the 
baseline strategy, the additional per person cost was $404 with gains 
in QALYs of 0.0154 resulting in an incremental cost-effectiveness ratio 
of $26,286/QALY gained (Table 1). The ICER was most sensitive to 
the false negative rate of the genetic test among NDBE patients and 
the cost of sponge-based genetic testing.
Conclusion
Sponge-based surveillance+genetic testing was cost-effective 
when compared to the current practice of endoscopy+biopsy 
surveillance. Sensitivity analyses demonstrated that the magnitude 
of cost-effectiveness was dependent on critical parameters, such as 
sensitivity of the genetic test, uptake of the novel non-endoscopic 
surveillance method and cost of the genetic test. In order for the 
sponge-based genetic test strategy to be cost effective it will need 
to have a sensitivity of 50% or better relative to that of the current 
surveillance strategy (Endoscopy+biopsy).
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